Business Context and Reporting Period
Company: BioNexus Gene Lab Corp. (BGLC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: BGLC operates through three segments: MRNA Scientific (genomic screening services), Chemrex (industrial chemical trading transitioning to CDMO), and Investment Holding (including digital asset treasury strategies). The company is a smaller reporting company and emerging growth company listed on Nasdaq.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $22,842 | $2,137,075 |
| Gross Profit/(Loss) | $(790) | $343,493 |
| Net Loss | $(543,575) | $(623,327) |
| Diluted EPS | $(0.225) | $(0.347) |
| Cash & Cash Equivalents | $2,397,977 | $2,089,438 |
| Total Assets | $9,040,130 | $9,252,784 |
| Total Liabilities | $946,877 | $637,856 |
| Working Capital | $4,399,432 | $4,927,781 |
| Operating Cash Flow | $(147,671) | $(824,072) |
Note: Gross margin for Q1 2026 was negative (-3.46%) compared to 16.07% in Q1 2025.
Material Changes vs. Prior Period
- Revenue Collapse: Revenue decreased by 99% year-over-year, primarily driven by a 99% drop in the Chemrex segment due to operational disruptions caused by former management actions. MRNA Scientific revenue also declined 57% due to lower sales volume.
- Expense Reduction: Total operating expenses decreased 43% to $597,386, largely due to reduced sales and marketing spend at Chemrex following management changes.
- Loss Narrowing: Net loss improved by 13% to $543,575, despite the revenue collapse, due to significant expense reductions.
- Provision for Credit Losses: A significant provision of $202,497 was recorded for expected credit losses in Q1 2026, compared to $40,124 in the prior year, reflecting higher risk assessments for Chemrex receivables.
- Liquidity: Cash and cash equivalents increased to approximately $2.4 million, supported by financing activities and reduced operating cash burn.
Outlook, Risks, and Unusual Items
- Strategic Partnerships: The company secured exclusive commercial rights to the VitaGuard™ MRD platform in the ASEAN region via an agreement with Fidelion Diagnostics (closed Nov 2025). Deployment is scheduled to commence in 2026.
- Capital Raising: An At-The-Market (ATM) program with Maxim Group LLC is active, allowing for the sale of up to $20 million in common stock. Additionally, an Equity Purchase Agreement with ARC Group International Ltd. provides access to up to $500 million in financing over 36 months.
- Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern due to accumulated deficits and operating losses, though management believes current liquidity and financing options are sufficient for the next 12 months.
- Legal Proceedings: In May 2026 (subsequent event), the company issued Letters of Demand to five former Chemrex officers/directors seeking repayment of approximately $2.94 million in unauthorized transactions.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses at the Chemrex subsidiary related to transaction approvals and documentation. Remediation is ongoing.
- Digital Assets: While an Ethereum treasury strategy was approved in March 2025, the company held no digital assets as of March 31, 2026, pending final allocation strategies.
Investor Verification Checklist
- Revenue Sustainability: Verify the timeline for Chemrex's transition to a CDMO model and the expected ramp-up of MRNA Scientific's VitaGuard™ platform to replace lost chemical trading revenue.
- Receivables Quality: Assess the collectability of Chemrex trade receivables given the $202k provision and the legal action against former management.
- Internal Control Remediation: Monitor the progress of the remediation plan for Chemrex's internal controls to ensure future financial reporting reliability.
- Capital Dilution: Review the terms and potential dilution impact of the ARC Group $500M facility and the ongoing ATM program.
- Legal Recovery: Track the outcome of the $2.94M demand against former officers to determine if this will result in a cash recovery or further legal costs.